Vaso Corp (VASO): R&D Expense
$728.0K
Year ended 2025-12-31
$778.0K
Trailing 12 months to 2026-06-30
+6.4%
3-year compound annual growth
-0.5%
5-year compound annual growth
+3.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $728.0K | -14.5% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $851.0K | +12.7% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $755.0K | +24.8% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $605.0K | -64.8% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $1.72M | +131.0% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $745.0K | -8.4% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $813.0K | -8.2% | 2021-05-05, From 2019-01-01 |
| 2018-12-31 | $886.0K | -6.2% | 2020-04-14, From 2018-01-01 |
| 2017-12-31 | $945.0K | +78.3% | 2019-04-15, From 2017-01-01 |
| 2016-12-31 | $530.0K | +2.9% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $515.0K | -35.9% | 2017-03-30, From 2015-01-01 |
| 2014-12-31 | $803.0K | +16.5% | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | $689.0K | +19.6% | 2015-03-30, From 2013-01-01 |
| 2012-12-31 | $576.0K | n/a | 2014-03-27, From 2012-01-01 |
| No annual figure between 2011-05-31 and 2012-12-31. | |||
| 2011-05-31 | $462.0K | n/a | 2013-04-01, From 2010-06-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vaso Corp (VASO) | 2025-12-31 | $728.0K | -14.5% |
| Ceribell, Inc. (CBLL) | 2025-12-31 | $19.14M | +41.2% |
| Biolife Solutions Inc (BLFS) | 2025-12-31 | $7.57M | +59.3% |
| Electromed, Inc. (ELMD) | 2026-06-30 | $1.31M | +31.9% |
| Outset Medical, Inc. (OM) | 2025-12-31 | $21.23M | -44.7% |
| Iridex Corp (IRIX) | 2026-01-03 | $3.67M | -32.7% |
| Axogen, Inc. (AXGN) | 2025-12-31 | $32.88M | +18.4% |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $9.38M | -3.9% |
| electroCore, Inc. (ECOR) | 2024-12-31 | $2.36M | -55.6% |
Compare VASO, CBLL, BLFS, ELMD side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗